HIPRA participates in a research project that aims to design therapies that limit the impact of the West Nile virus (WNV), an emerging pathogen for which there is currently no treatment or vaccine for use in humans.

The project is coordinated by the IrsiCaixa AIDS Research Institute and funded by the European Union research program Horizon-Europe.

All research centres will work on the development of a safe and effective prophylactic vaccine against WNV that can induce a prolonged immune response over time and protect the entire population. Within the same project, called LWNVIVAT (from its name Limiting West Nile Virus Impact by Novel Vaccines And Therapeutics Approaches), the scientific team will design, produce, and analyze the efficacy and therapeutic potential of specific antibodies for the virus, in addition to the vaccine.